3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Melanoma
4
Polycythemia Vera
1
Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
ruxolitinib
16
Hydroxyurea
7
givinostat hydrochloride
5
givinostat
5
Phlebotomy
3
Aspirin
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
bomedemstat
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
LY2784544
2
spartalizumab
1
sonidegib
1
sabatolimab
1
pomalidomide
1
pelcitoclax
1
peginterferon alfa-2b
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
navitoclax
1
lestaurtinib
1
itacitinib
1
imetelstat
1
anagrelide
1
RG7388
1
Pipobroman
1
Panobinostat
1
ON 01910
1
NIS-793
1
Lenalidomide
1
INCB039110
1
Fentanyl
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Polycythemia Vera
×
peginterferon alfa-2b
×
Clear all
NCT01949805
2016-11-28
PROUD-PV
AOP Orphan Pharmaceuticals AG
Phase 3
Completed
257 enrolled